Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONO-LINYAH vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Moderate to severe plaque psoriasis,Psoriatic arthritis,Ankylosing spondylitis,Non-radiographic axial spondyloarthritis
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
10 mg orally once daily
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (Cr Cl <30 m L/min) and in neonates.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Metabolized via general protein degradation pathways; not primarily metabolized by CYP450 enzymes.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
20–30% bound to albumin.
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
0.5–0.8 L/kg, consistent with distribution into total body water; increased in edema or ascites.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral bioavailability is 60–70% (first-pass metabolism ~30–40%); immediate-release tablets.
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Weight <20 kg: 2.5 mg once daily; 20-40 kg: 5 mg once daily; >40 kg: 10 mg once daily
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Start at 5 mg once daily; titrate based on response and tolerability
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
None
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Increased risk of infections,Hypersensitivity reactions,Hepatotoxicity,Inflammatory bowel disease exacerbation
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Hypersensitivity to active substance or excipients,Clinically significant active infection
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol as it may impair liver function.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydramnios, fetal renal impairment, and neonatal anuria. Contraindicated in all trimesters.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Excreted in human milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., renal toxicity), breast-feeding is contraindicated during therapy and for at least 30 days after last dose.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, immediate discontinuation is required; no dose adjustment is recommended as alternative therapy should be initiated.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
Mono-Linyah (ethinyl estradiol and norgestimate) is a combined oral contraceptive. Counsel patients about the increased risk of venous thromboembolism (VTE), especially in smokers over 35. Missed pill instructions vary by how many are missed. Consider drug interactions with rifampin, certain anticonvulsants (e.g., carbamazepine, phenytoin), and St. John's Wort, which may reduce efficacy. Use with caution in patients with a history of migraine with aura, as it may increase stroke risk.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one pill daily at the same time each day to maintain effective hormone levels.,If you miss a pill, follow the package insert instructions or consult your healthcare provider.,Use a backup contraceptive method (e.g., condoms) if you miss pills or if you have vomiting or severe diarrhea.,This medication does not protect against HIV or other sexually transmitted infections.,Smoking while using this pill increases your risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain/swelling, chest pain, shortness of breath, or severe headache.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONO-LINYAH vs DESOGEN, answered by our medical review team.
MONO-LINYAH is a Combination Oral Contraceptive that works by Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONO-LINYAH and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONO-LINYAH is: 10 mg orally once daily. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONO-LINYAH and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONO-LINYAH is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydr. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.